Evidence map›Paper›PMID 31566060›Full record

ArticleSLAS discovery : advancing life sciences R & D2020

High-Throughput Cellular Thermal Shift Assays in Research and Drug Discovery.

Mark J Henderson, Marc A Holbert, Anton Simeonov, Lorena A Kallal

Abstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Article
  3. Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  4. Article
  5. Targeting IPNature communications · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Target Engagement Assays in Early Drug Discovery.Journal of medicinal chemistry · 2025
    Review
  11. Review
  12. Article
  13. Integrative analysis of KCNQ1 variants reveals molecular mechanisms of type 1 long QT syndrome pathogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  14. Article
  15. Hapalindole Q suppresses autophagosome-lysosome fusion by promoting YAP1 degradation via chaperon-mediated autophagy.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. The Knowns and Unknowns in Protein-Metabolite Interactions.International journal of molecular sciences · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mark J HendersonNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0001-8590-7338
Marc A HolbertProtein, Cellular, & Structural Sciences, GlaxoSmithKline, Collegeville, PA, USA.
Anton SimeonovNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Lorena A KallalScreening, Profiling, and Mechanistic Biology, GlaxoSmithKline, Collegeville, PA, USA.

Funding

Development of high-throughput CETSA target engagement assaysZIATR000406 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI HENDERSON, MARK · 2020 to 2025
$1.1M
Intramural NIH HHS ZIA TR000406
6 · The paper itself

Abstract

Thermal shift assays (TSAs) can reveal changes in protein structure, due to a resultant change in protein thermal stability. Since proteins are often stabilized upon binding of ligand molecules, these assays can provide a readout for protein target engagement. TSA has traditionally been applied using purified proteins and more recently has been extended to study target engagement in cellular environments with the emergence of cellular thermal shift assays (CETSAs). The utility of CETSA in confirming molecular interaction with targets in a more native context, and the desire to apply this technique more broadly, has fueled the emergence of higher-throughput techniques for CETSA (HT-CETSA). Recent studies have demonstrated that HT-CETSA can be performed in standard 96-, 384-, and 1536-well microtiter plate formats using methods such as beta-galactosidase and NanoLuciferase reporters and AlphaLISA assays. HT-CETSA methods can be used to select and characterize compounds from high-throughput screens and to prioritize compounds in lead optimization by facilitating dose-response experiments. In conjunction with cellular and biochemical activity assays for targets, HT-CETSA can be a valuable addition to the suite of assays available to characterize molecules of interest. Despite the successes in implementing HT-CETSA for a diverse set of targets, caveats and challenges must also be recognized to avoid overinterpretation of results. Here, we review the current landscape of HT-CETSA and discuss the methodologies, practical considerations, challenges, and applications of this approach in research and drug discovery. Additionally, a perspective on potential future directions for the technology is presented.

Indexed as

Biomedical ResearchDrug DiscoveryHigh-Throughput Screening AssaysHumansLigandsLigandscell-based assaysCETSAdrug–target interactiontarget engagementthermal shift

Identifiers

PMID31566060
PMCPMC10915787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.